Dr. Oh on the Use of Abiraterone and Docetaxel in mCRPC
William K. Oh, MD
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).
The use of abiraterone and docetaxel was established in mCRPC, and there are many conversations about combinations. There are currently no clear answers to these questions.